REGISTER
MedJ at JSCO 2025 with Dr. Yasushi Goto
MedJ at JSCO 2025 with Dr. Yasushi Goto is examined through new evidence rather than broad claims. It pulls together the main findings on JSCO, ADC, medj and shows what they may mean for diagnosis, monitoring, prevention, or treatment.

Yasushi Goto, National Cancer Center Hospital, Japan

How to redesign drug therapy systems in an era of population decline? An in-depth analysis of opportunities and challenges for ADC drugs in lung cancer to achieve this vision.

0
0
Loading